Novartis has agreed to pay $245M to settle a lawsuit claiming the company attempted to delay the launch of generic copies of its Exforge blood-pressure medicine, Marthe Fourcade of Bloomberg reports. If the settlement is approved by a judge, it will resolve all outstanding claims on the matter for Novartis, Bloomberg added, citing an emailed statement made by the company. Reference Link
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on NVS:
- Sandoz Canada supports Ontario policy change on biosimilars
- Novartis call volume above normal and directionally bullish
- Harrow Health signs binding agreement to acquire rights to ophthalmic products
- Cantor biotech/biopharma analysts hold an analyst/industry conference call
- Novartis reports Phase 3 APPLY-PNH trial met both primary endpoints
